- Home
- RPRX vs ACM Comparison
RPRX vs ACM Comparison
Compare RPRX & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- ACM
- Stock Information
- Founded
- RPRX 1996
- ACM 1980
- Country
- RPRX United States
- ACM United States
- Employees
- RPRX N/A
- ACM N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- ACM Military/Government/Technical
- Sector
- RPRX Health Care
- ACM Consumer Discretionary
- Exchange
- RPRX Nasdaq
- ACM Nasdaq
- Market Cap
- RPRX 13.9B
- ACM 14.7B
- IPO Year
- RPRX 2020
- ACM 2007
- Fundamental
- Price
- RPRX $36.46
- ACM $115.30
- Analyst Decision
- RPRX Strong Buy
- ACM Strong Buy
- Analyst Count
- RPRX 3
- ACM 8
- Target Price
- RPRX $47.33
- ACM $119.88
- AVG Volume (30 Days)
- RPRX 4.4M
- ACM 978.2K
- Earning Date
- RPRX 08-07-2025
- ACM 08-04-2025
- Dividend Yield
- RPRX 2.42%
- ACM 0.90%
- EPS Growth
- RPRX 37.60
- ACM N/A
- EPS
- RPRX 2.45
- ACM 4.58
- Revenue
- RPRX $2,263,845,000.00
- ACM $16,047,510,000.00
- Revenue This Year
- RPRX $29.35
- ACM $3.26
- Revenue Next Year
- RPRX $7.58
- ACM $5.98
- P/E Ratio
- RPRX $14.83
- ACM $24.79
- Revenue Growth
- RPRX 1.13
- ACM 4.55
- 52 Week Low
- RPRX $24.05
- ACM $82.23
- 52 Week High
- RPRX $36.43
- ACM $118.56
- Technical
- Relative Strength Index (RSI)
- RPRX 64.64
- ACM 70.43
- Support Level
- RPRX $35.01
- ACM $111.02
- Resistance Level
- RPRX $36.33
- ACM $114.70
- Average True Range (ATR)
- RPRX 0.63
- ACM 1.80
- MACD
- RPRX 0.05
- ACM 0.07
- Stochastic Oscillator
- RPRX 90.72
- ACM 96.72
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.